DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for hypertrophic cardiomyopathy 7 — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHypertrophic cardiomyopathy 7 maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hypertrophic cardiomyopathy 7 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Hypertrophic cardiomyopathy has been recognised since the late 1950s, and its clinical identification, morphology, pathophysiology, and natural history have been studied extensively, yet intrinsic complexities continue to create uncertainty and debate. The disease is characterised by left ventricular hypertrophy and diastolic dysfunction, and it carries a risk of sudden cardiac death. Causes include genetic mutations and mitochondrial dysfunction, but the precise relationship between these factors remains unclear. The disease has a very high prevalence in the general population, approximately 1 in 500, with marked diversity in course. The majority of patients have a benign clinical course and normal life expectancy, but some are at risk for sudden cardiac death, severe arrhythmia, and progressive heart failure. A case report describes a female patient diagnosed as a child at age 10, followed clinically and echocardiographically, who began to develop signs and symptoms of heart failure at age 44.
By 2024, scientific knowledge of hypertrophic cardiomyopathy had improved significantly, with advances in understanding pathogenesis, imaging methods, genetic analysis, and characterisation of natural history. These developments have reformulated the clinical and prognostic significance of the disease and have been accompanied by the development of new medications addressing molecular mechanisms linked to pathophysiology and pathogenesis. In 2022, a review of progress in clinical treatment noted that hypertrophic cardiomyopathy can be caused by hypertension, aortic stenosis, and other factors, with clinical manifestations including dyspnoea, precardiac pain, fatigue, and palpitations, and that it can ultimately progress to heart failure. The review stated that the clinical incidence is increasing year by year and that complications are numerous, but it did not report any specific treatment outcomes or quantitative results from either Chinese or Western medicine.
No abstract reports any controlled trial, survival data, response rates, or sample sizes for any drug therapy. The 2024 guidelines mention new medications but give no numbers. The 2023 scoping review on genetic mutations and mitochondrial dysfunction states that understanding early mechanisms is crucial for developing effective therapies but does not present any treatment data. What is still missing are large, randomised controlled trials with hard endpoints such as survival or hospitalisation, adequate funding for such trials, and patient stratification by genotype or phenotype to identify who might benefit from any emerging therapy.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
New England Journal of Medicine · 1987 · 900 citations
Hypertrophic Cardiomyopathy
Abstract(First of Two Parts)HYPERTROPHIC cardiomyopathy has fascinated and often confused physicians for the quarter of a century since its recognition in the late 1950s.1 2 3 4 5 During this time, investigators have assembled an impressive array of observations spanning numerous aspects of the clinical identification, morphology, pathophysiology, and natural history of the disease. Much understanding has emerged from these investigative efforts; however, the intrinsic complexities of hypertrophic cardiomyopathy continue to create uncertainty and debate.Numerous studies have explored specific facets of hypertrophic cardiomyopathy, and several have comprehensively reviewed the broader aspects of its clinical profile and course, including the findings on physical . . .
Arquivos Brasileiros de Cardiologia · 2024 · 24 citations · open access
Guidelines on the Diagnosis and Treatment of Hypertrophic Cardiomyopathy - 2024
Abstract1. Introduction Scientific knowledge of hypertrophic cardiomyopathy (HCM) has significantly improved in the past decades. A better understanding of its pathogenesis, significant advances in the use of imaging methods, and the more common application of genetic analysis, in addition to a better characterization of the natural history of this myocardial disease, have profoundly reformulated its clinical and prognostic significance. Conversely, these processes were accompanied by the development of new medications addressing molecular mechanisms intrinsically linked to the pathophysiology and pathogenesis [...]
Journal of Contemporary Medical Practice · 2022 · 0 citations · open access
Progress in Clinical Treatment of Hypertrophic Cardiomyopathy with Traditional Chinese and Western Medicine
AbstractHypertrophic cardiomyopathy refers to cardiac hypertrophy caused by hypertension, aortic stenosis and other factors, with dyspnea, precardiac pain, fatigue, palpitations and other clinical manifestations, and ultimately can progress to heart failure; The clinical incidence of this disease is increasing year by year, and the complications are numerous, which seriously affect the prognosis. For the treatment of this disease, Chinese and western medicine have their own opinions, through combing the latest domestic and foreign relevant literature, systematically elaborated in recent years about the progress of Chinese and western medicine treatment of this disease, for the majority of doctors reference.
Genetic Mutations and Mitochondrial Dysfunction as Modulating Factors in Hypertrophic Cardiomyopathy: An Updated Scoping Review
AbstractHypertrophic cardiomyopathy (HCM) is a cardiac condition characterized by left ventricular hypertrophy and diastolic dysfunction, posing a risk of sudden cardiac death. The causes of HCM are diverse, including genetic mutations and mitochondrial dysfunction, but the precise relationship between these factors remains unclear. This project focuses on investigating this association, as understanding the early mechanisms of HCM is crucial for the development of effective therapies, aiming to contribute to future advances in the treatment of this cardiac condition.
Srce i krvni sudovi · 2014 · 0 citations · open access
Case of the patient with non-obstructive hypertrophic cardiomyopathy regarding to European guidelines on diagnosis and management of hypertrophic cardiomyopathy
AbstractHypertrophic cardiomyoparthy is disease with very high prevalence in general population (1~500). There is marcable diversity in disease course. Majority of patients have benign clinical course and normal life expactancy but some are in risc for sudden cardiac death, severe arrhythmia and progressive heart failure. We present a case of female patient who was diagnosed with hypertrophic cardiomyopathy as a child (10years). She was clinicaly and echocardiographicly followed up in our clinic. When she was 44 years old signs and symptoms of heart failure started to develop.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
